On February 10, 2004, WLF filed comments with the Centers for Medicare and Medicaid Services (CMS) in opposition to the agency’s national coverage reviews of four advanced anti-cancer drugs. CMS administers the Medicare program. The agency has announced that it is considering whether to deny reimbursement for off-label uses of key drugs for colorectal cancer and non-Hodgkin’s lymphoma, which kill thousands of Americans annually. WLF, joined by the Abigail Alliance and the Lorenzen Cancer Foundation, argued that off-label prescribing is vital to cancer treatment and that CMS lacks the authority to deny coverage of these medicines.